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Type 2 diabetes is a worldwide disease reaching epidemic dimensions. The rapid progression
of  the disease urgently calls for both a broader and deeper understanding of its pathophysi-
ology. In line with this statement, the Human Diabetes Proteome Project (HDPP) was ofﬁcially
launched at the 11th HUPO meeting in Boston, 2012. A special session was dedicated to this
new  initiative, gathering experts in the main topics related to diabetes and its associated
complications. Key issues were debated with a focus on how deranged circulating glucose
and  free fatty acids induce dysfunction. It has been decided that HDPP will therefore focus oniabetes
uman proteome
studying the early stages of diabetes that lead to abnormal glucose and lipid levels. The ini-
tiative will initially focused on islets of Langerhans, insulin-producing cell lines, and blood
 diabetes-related cohorts. In subsequent stages HDPP will investigatehuman samples fromslet
eta-Cell
besity
target tissues in which glucose and lipids could promote protein dysfunctions. Omics-rooted
systems approaches enhanced by bioinformatics will be deployed to unravel effects of lipids
and  glucose triggering diabetes initiation and progression. A ﬁrst milestone has been deﬁned
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Glucose
Fatty acids
for the 12th HUPO meeting in Yokohama, 2013: the 1000 diabetes-associated protein (the
1000-HDPP) database, i.e. a freely available internet resource (www.HDPP.info) of more than
1000  proteins with links to their corresponding proteotypic peptides, afﬁnity reagents and
protein-speciﬁc biological/biomedical information.
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1.  Introduction
Epidemiological data from late 19th-century described dia-
betes mellitus (from the Greek “pass through” and Latin “sweet
as honey”) as a rather frequent disorder in man, in obese peo-
ple above 50 years old, in cities and in western countries [1].
This classiﬁed diabetes as a disease of modern urban life.
There are two main types of diabetes: (1) insulin-dependent
diabetes mellitus (type 1 diabetes), which is an autoimmune
disorder, and (2) non-insulin-dependent diabetes mellitus
(type 2 diabetes), which is a complex multi-factorial disease.
Type 2 diabetes (90% of the diabetic population) [2] affects
nearly 150 million persons and is considered by WHO  to
reach soon epidemic proportions. Diabetes is a global public
health problem with high costs and suffering primarily due
to long term complications. The pathogenic process involves
complex interactions between genetic and environmental
factors. Type 2 diabetes is characterized by an abnormal
glucose homeostasis leading to hyperglycemia. The glucose
of patients affected by type II diabetes. In addition, factors
including diet, stress, exercise, aging and obesity seem to
play a major role in the development of the disease. The
long-term complications associated with diabetes lead to
chronic degenerative complications. They have been classiﬁed
as macro-vascular (atherosclerosis and subsequent classical
consequences such as stroke and myocardial infarction) and
micro-vascular complications (nephropathy, retinopathy and
neuropathy). However, the relationship between the metabolic
disorders and these complications is not clearly understood.
For that reason, a better understanding of the early patho-
physiological mechanisms causing multiple organ and cell
type dysfunction is required to further development of more
efﬁcient treatments. Diabetes is a complex condition with
genetic, environmental and lifestyle factors. Therefore, only a
highly interdisciplinary international collaboration can deliver
the multidimensional insights needed to unravel the dynam-
ics of cellular pathways that are of key interest in diabetes and
its associated complications.
We propose here to leverage a worldwide constellation of
expertise into a Human Diabetes Proteome Project (HDPP)
 © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.homeostasis deregulation is mainly due to a combination of
insulin resistance and defects in insulin secretion. Many can-
didate genes have been reported to be associated with both
defects, however none of them accounts for the majorityinitiative to generate systems-level insights into diabetes-
associated cellular changes by gathering multivariate data
sets over time from specialized cells and organs of healthy and
diabetes-affected individuals. Longitudinal systems biology
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ata sets will be collected from human body ﬂuids, organs
nd cells, as well as from cellular and animal model systems
f the disease. The results generated by the consortium will
e made available to the wider research community by means
f public repositories and data integration platforms such as
eXtProt [3].
The HDPP is not only expected to deliver comprehensive
nformation on disease mechanisms but also to identify pro-
eins and isoforms associated with diabetic pathogenesis and
omplications that are crucial for the development of better
iagnostics, therapies and prevention strategies. The integra-
ion of HDPP into the overarching Human Proteome Project
HPP) [4] initiative opens favorable conditions for information
xchange and collaboration across all the Chromosome and
iology/Disease HPP (C-HPP [5] and B/D-HPP [6]) initiatives.
.  Network  biology  of  glucolipotoxicity
iabetes occurs when insulin secretion is inadequate and
an no longer maintain normoglycemia. Failure of the beta-
ell secretory machinery has been suggested as a primary
ause for the reduced insulin secretion but loss in beta-cell
ass by a skewed ratio of apoptosis versus proliferation has
lso been suggested [7–9]. It has been demonstrated that
 tight control of glycemia in T2DM improves insulin sen-
itivity and secretion, suggesting a toxic effect of elevated
lucose levels on beta-cells and insulin target cells [10]. Indeed,
rolonged exposure of beta-cells to high levels of glucose
ecreases insulin secretion [11]. Not only glucose but also fatty
cids cause harmful actions depending on their concentra-
ion and exposure time [12]. Chronic high glucose and lipid
xposures modify a number of biological pathways includ-
ng the expression of glucose and lipid metabolic enzymes as
ell as transcription factors. Two concepts have thus emerged:
lucotoxicity and lipotoxicity. The concept of glucolipotoxi-
ity with the hypothesis that elevation of both glucose and
at synergize their toxicity on cells has also been proposed,
here glucose-induced reduction in fat oxidation and pro-
otion of lipid esteriﬁcation in beta-cells could contribute
13,14]. This concept is potentially complementary to the fact
hat reactive oxygen species (ROS) and glycation of proteins
re implicated in both glucotoxicity and lipotoxicity induc-
ng cell apoptosis [15]. The goal of the HDPP initiative is to
nderstand the complexity of cellular responses through the
se of large-scale network biology-based approaches on vari-
us specialised cells and tissues. This network based approach
ill allow to dissect the regulatory mechanisms that underlie
he detrimental effects of glucose and lipids, and potentially
evelopment of new therapeutic drugs protecting cells and
rgans from the toxicity of excess of these molecules.
.  The  target  disease:  diabetes
ype 1 as well as type 2 diabetes are progressive diseases.
heir progression is associated with numerous complications
uch as micro- and macrovascular disease, retinopathy, neu-
opathy, nephropathy and obesity. The HDPP consortium aims
t increasing the overall knowledge about the diabetes-related i c s 1 ( 2 0 1 3 ) 3–11 5
pathology and associated phenomena. For this purpose, the
HDPP consortium has prepared a 10-years plan allowing the
different diabetes-associated problematics to be covered. Dur-
ing the ﬁrst phase, partners intend to focus their work on islets
of Langerhans, insulin-producing cell lines, and blood samples
from diabetes-related cohorts as these are already accessible
through various existing omics datasets. In a second phase,
the work will be extended to hepatocytes, muscle tissue, neu-
rons, adipose tissue, vascular endothelial cells, retina, kidney,
plasma/serum, erythrocytes, peripheral blood mononuclear
cell (PBMC), platelets, lacrimal ﬂuid, and saliva. Cell line mod-
els that might be representative of the above tissues will also
be studied in this phase. Moreover, even if human samples
are of greatest interest, other species samples are available
and have other advantages. For instance, datasets from rodent
beta-cells are already available to be included in the HDPP
initiative.
The HDPP plan includes working at different lev-
els of knowledge. The aim is to gather datasets from
proteomics, peptidomics, lipidomics, metabolomics, tran-
scriptomics, epigenomics, but also modiﬁcations of interest
in the ﬁeld such as glycation, acetylation and palmitoyla-
tion. Mapping the diabetes related data on existing interaction
networks will be the ﬁrst step in data integration. This will
lead to a better understanding of the pathways involved in
diabetes. Furthermore, networks will be generated from each
new dataset. On each resulting network, public available func-
tional annotations, pathways and Gene Ontology terms will
be mapped. This will lead to an extension of the existing
networks but also help to focus on relevant nodes and edges
within the network.
Our future generated datasets and those already avail-
able will be integrated in public repositories and databases
to share them with the research community. NeXtProt [3]
that integrates UniProtKB/Swiss-Prot [16,17] for provision of
gold standard protein function is hereby the starting point.
Moreover, high-throughput experimental datasets such as the
one provided by the Human Protein Atlas [18] are our central
resource for antibody-based catalogue and tissue microarrays.
ProteomeXchange [19] and PeptideAtlas [20] will be used for
exchanging and addressing the challenge of reanalysis and
ﬁnally to access to the primary experimental mass spectrom-
etry data.
The long-term goal of HDPP is to identify and understand
the cellular pathways that are of central interest in diabetes
and its associated complications. A better understanding of
the decline in cellular function the occurs in diabetes is
expected to reveal new target pathways and thereby help
develop treatments to decelerate and even arrest the dis-
ease process by restoring normal cellular function. HDPP will
develop and apply network biology to highlight mechanisms
related to the biological effects of glucose and lipids. The HDPP
project goals and deliverables are based on the three HPP pil-
lars: (1) build and expand the diabetes proteome knowledge
base, which we  will implement using data integration tech-
niques, (2) augment speciﬁc diabetes-relevant protein binding
reagents, which will be realized by development of novel and
cataloging of already available protein afﬁnity reagents, and
(3) enhance mass spectrometric tools for these proteins and
peptides.
 t e o m i c s 1 ( 2 0 1 3 ) 3–11
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4.  Initiative  structure
As one of the B/D-HPP initiatives, the HDPP will be structured
to match HUPO requirements [3,6,21,22]. Working groups were
created within the consortium in order to fulﬁll the various
milestones established in the initiative. Additionally a man-
agement structure was created to lead the project.
4.1.  Working  groups  (WGs)
Working groups were ﬁrst set as presented in Table 1, but will
evolve during 2013 as projects will be precisely deﬁned.
4.2.  Management  and  structure
The core of the decision making structure is composed of the
Project Coordinator (PC) and Project Management Committee
(PMC) (Fig. 2). The PMC  will be composed of a representative
of each working group and partner and of the PC. This struc-
ture insures the coordination and the management of the
project with several decision levels including global strategy
and assessment of HDPP. The aspects related with dissemina-
tion for an appropriate diffusion of the results of the projects
are dealt by the PMC  as well.
4.2.1.  Milestones
The project has speciﬁc milestones that are set for monitoring
progress. The milestones will also be a way to verifying that
the HDPP activities in terms of obtained and expected results
are in agreement with the B/D-HPP milestones.
4.2.2.  Information  exchange
Working documents, minutes of meetings, bibliography, data,
publications and presentations given on behalf of HDPP will
be available on the web-based platform (www.HDPP.info). The
aim of the website is to serve as a communication platform for
the partners of the HDPP project. The website is build using
the Drupal content management system [23]. It is hosted by
the University of Geneva and is available at www.HDPP.info
to the public. The Drupal based system has been extended
by an email contact form, user and mailing-list manage-
ment and an internal area. Keeping security in mind, all
conﬁdential content is only accessible at the internal area of
Table 1 – Description of the HDPP Working Groups (WG).
Groups Themes
WG1 Obesity related to diabetes
WG2 Neuropathies related to diabetes
WG3 Retinopathies related to diabetes
WG4 Nephropathies related to diabetes
WG5 Macro-vascular diseases (atherosclerosis)
WG6 Omics platforms
WG7 Post-translational modiﬁcations (glycation and
palmitoylation)
WG8 Databases
WG9 Computational biology
WG10 HPP integration
WG11 Funding
WG12 Management and disseminationFig. 2 – Structure of the HDPP initiative.
website after secured login. Fig. 1 shows the login form of the
website.
The latest news on project status and upcoming events are
published on a blog, which serves as front-page. In the future,
the website will become the central resource of HDPP diabetes-
related knowledge. All tools developed for the integration
of omics data and their analyses will be made available on
it.
5.  Deliverables  and  key  research  projects
The ﬁrst short-term objective of the HDPP project is to gather
knowledge on diabetes and related complications already
acquired by the different partners. Data on human islets,
rodent beta-cells, and blood glycation are already accessi-
ble from partners’ research projects as described in this
section. They will be grouped and further processed using
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ioinformatics tools to enhance current knowledge of key dia-
etes pathways. This ﬁrst leveraged knowledge base will be
urther enhanced by integration of results from additional
DPP projects.
.1.  The  1000  diabetes-related  proteins:  the
000-HDPP
he ﬁrst deliverable for HDPP is to generate a list of proteins
hat are of central interest for the condition of diabetes. This
ist (supplementary data 1) was generated from the neXtProt
atabase, by ﬁrst searching this public domain with speciﬁc
ey words related to different subtypes of diabetes, and then
y expert validation of the retrievals.
Supplementary material related to this article found, in the
nline version, at doi:10.1016/j.trprot.2013.03.002.
The actual list comprises 1379 proteins, and will fur-
her evolve and mature over time. Each entry contains:
he protein and gene names; the neXtProt/UniProtKB acces-
ion number; the SRM/PeptideAtlas and Human Protein
tlas cross-references; a list of available protein binding
eagents; the chromosome location; and the number of iso-
orms/variants/PTMs. This resource is already available on the
DPP website (www.HDPP.info).
.2.  The  human  islet  of  Langerhans  proteome
atabase
 proteomic analysis in the context of the Beta-JUDO
roject (see Section 5.5) allowed the identiﬁcation of more
han 5300 human islet-related proteins by Gas-Phase Frac-
ionation mass spectrometry. The resulting dataset has
een submitted to PRIDE (27518-27529) via ProteomeXchange
10.6019/PXD000050). Furthermore, this list was used by
eXtProt to upgrade the protein existence level of some pro-
eins. A brief overview of the identiﬁed proteins can be found
n supplemental data 2. Each entry contains the same type of
ata than the 1000-HDPP list.
Supplementary material related to this article found, in the
nline version, at doi:10.1016/j.trprot.2013.03.002.
.3.  The  rodent  beta-cell  proteome  database
he rat insulin-secreting cell line INS-1 was established in
992 [24]. It is probably the most widely used clonal cell model
n beta-cell research. Several proteomics datasets on total cell
25] and sub-cellular fractions [26] have been obtained from
his slowing growing rat insulinoma beta-cell with more  than
500 identiﬁed proteins. The list is in supplementary data
. Each entry contains the UniProtKB accession number, the
ame and the gene name.
Supplementary material related to this article found, in the
nline version, at doi:10.1016/j.trprot.2013.03.002.
.4.  The  human  blood  glycated  proteome  databasen analysis of glycated proteins in biological samples could
ive new insights into the characterization of the blood gly-
ated proteome [27]. Therefore a qualitative/quantitative
pproach has been developed. Hyperglycaemia is a i c s 1 ( 2 0 1 3 ) 3–11 7
conditioning factor promoting the non-enzymatic glyca-
tion of proteins in those sites kinetically favored. The blood
glycated proteome is dynamic and evolves qualitatively and
quantitatively with unbalanced glucose concentration. For
this reason, it is interesting to obtain proﬁles containing
information of glycation sites as a function of hypergly-
caemia level. The application of the analytical approach
has revealed the identiﬁcation of 35 glycated proteins in
normoglycaemic plasma with detection of 113 glycation
sites [27]. The list of glycated proteins is in supplementary
data 4. Complementarily, human hemolysates with differ-
ent levels of hyperglyacemia have also been analysed with
the same approach revealing quantitative modiﬁcations
of the glycation proﬁle with the concentration of glycated
haemoglobin [28]. The dynamic character of the blood gly-
cated proteome under hyperglycaemia justiﬁes using the
same approach to different blood fractions in order to under-
stand modiﬁcations occurring as a result of unbalanced
glucose homeostasis.
Supplementary material related to this article found, in the
online version, at doi:10.1016/j.trprot.2013.03.002.
5.5.  The  Islet  Human  Diabetes  Proteome  Project
(i-HDPP)
The insulin-producing beta-cell is located in the pancreatic
islets of Langerhans. In individuals with diabetes this cell type
is either lost (type 1 diabetes mellitus, T1DM) or function-
ally impaired (type 2 diabetes mellitus, T2DM). The prevalence
of especially T2DM in connection to obesity is rising [29]. To
halt the increase in the number of individuals developing
diabetes, gathering available information about which path-
ways are differentially activated in the islet under normal
conditions as well as during development of diabetes is cru-
cial.
Building an islet (i) resource by collecting available data sets
generated from the islet organ and beta-cell lines of human
and non-human origin will be central in the islet HDPP. Expres-
sion data sets obtained at different stages of the disease are
of particular interest. An additional aim of the i-HDPP is to
identify areas less investigated and stimulate and promote
research efforts in such areas.
Establishing links between past, present and future
research projects, where beta-cell pathway proﬁling is a com-
ponent, and the i-HDPP resource is an important task of the
initiative. An example of such interaction is the on-going FP7
project “Beta-cell function in juvenile diabetes and obesity”
(Beta-JUDO). This project is investigating the role of the beta-
cell in the development of obesity in young individuals. In
one part of the project human islets are exposed to different
conditions relevant for obesity development. This part of the
work has already allowed the identiﬁcation of 5300 human
islet-related proteins by mass spectrometry (see Section 5.2).
In the project, changes in human islet expression data sets
are subsequently generated and analyzed by network biology
strategies.Dysfunction or loss of the insulin-producing beta-cell is
the main factor in development of diabetes in both its forms.
The number of individuals developing diabetes is escalating.
Coordinating and making available existing and future islet
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beta-cell expression data sets may prove decisive in ﬁnding
novel strategies to halt the destructive beta-cell process pre-
cipitating the disease.
5.6.  Dysfunction  of  insulin-producing  cell  lines
induced  by  high  glucose
Given their role in insulin secretion and therefore in glucose
regulation beta-cells are pivotal in diabetes pathologies. It
is thus essential to increase our knowledge about beta-cell
function and dysfunction to gain insight into the disease. In
line with the HDPP, the aim of the project is to monitor pro-
teomic and transcriptomic modulation of insulin-producing
cell lines exposed to chronic high glucose levels, which is
a hallmark of type 2 diabetes. Stable isotope labeling with
amino acids in cell culture (SILAC) was applied to rat insu-
linoma INS-1E cell line grown either at intermediate or high
glucose levels. Whole cell extract as well as insulin secretory
granules (ISGs), mitochondria and nuclei were prepared. Pro-
teins were separated on SDS-PAGE, digested with trypsin, and
peptides were analyzed by LC-MS/MS. Proteins were identi-
ﬁed and quantiﬁed with MaxQuant [30]. Transcriptomic data
sets (n = 12) were generated under similar conditions using
Illumina ratref-12 expression bead-chips. Validation of the
protein localization and level of expression were performed by
qRT-PCR, western blots and immunoﬂuorescence. About 2500
proteins were identiﬁed in the sub-cellular INS-E fractions (see
Section 5.3). Among them, 33 displayed an expression signiﬁ-
cantly affected by high glucose concentration. These proteins
are mainly related to fatty acid metabolism, proliferation,
and apoptosis such as Neuronal Pentraxin 1, NP1. Bioin-
formatic integrations of these different rodent datasets will
contribute to the comprehension of glucose-induced effects
on beta-cells, and is therefore of high interest for the HDPP
project.
5.7.  Proﬁling  analysis  of  human  glycated  proteins  by
isotopic  labeling  with 13C-reducing  sugars
In the last years several efforts have been carried out to elu-
cidate the connection between glucotoxicity effects under
hyperglycemia and the wide spreading of systemic long-term
complications that occur under diabetes mellitus. High glu-
cose levels in the bloodstream (>11 mM)  tend to enhance the
kinetics of a non-enzymatic reaction involving sugar attach-
ment to protein speciﬁc sites. This process, termed glycation,
results in the impairment of proteins activity by the forma-
tion of adducts that affect recognition sites directly involved
with the protein function or, at long-term, by formation of
advanced glycation end products (AGEs) that alter the struc-
ture of proteins. Here, recent advances on the state-of-art of
glycation analysis are presented with an approach relying on
differential labeling of proteins with isotopically labeled glu-
cose ([13C6]-glucose). An incubation step with [13C6]-glucose
mimicking physiological conditions initiates this protocol to
label chemoselectively only the sites, which are prone to gly-
cation. Qualitative analyses are carried out by tandem mass
spectrometry after Glu-C protein digestion and boronate afﬁn-
ity chromatography for enrichment of glycated peptides. Two
orthogonal tandem mass spectrometry methods are used:m i c s 1 ( 2 0 1 3 ) 3–11
HCD-MS2 and CID-MS3 with neutral loss scanning. Quan-
titative analyses are based on the relative ratio between
MS1 precursor signals corresponding to endogenous glycated
peptides (labeled with [12C6]-glucose) and in vitro glycated
peptides ([13C6]-glucose). This experimental strategy enabled
to characterize and quantify the native glycation state of
proteins from human plasma and hemolysate (see Sec-
tion 5.4). Apart from that, predictive analyses intended to
evaluate qualitatively and quantitatively the effect of pro-
longed hyperglycaemia over the glycation proﬁle can be
planned. Further studies on the high-risk population of dia-
betic patients should provide new insights about the inﬂuence
of glycation on molecular and functional networks related
to hyperglycemia. For this reason, as described in Section
3, partners will initially focused on islets of Langerhans,
insulin-producing cell lines, and blood human samples from
diabetes-related cohorts. In subsequent stages the glycation
approach will be applied to target tissues in which hyper-
glycaemia could promote dysfunctions such as hepatocytes,
muscle tissue, neurons, adipose tissue, vascular endothelial
cells, retina, kidney, erythrocytes, peripheral blood mononu-
clear cell (PBMC), platelets, lacrimal ﬂuid, saliva and cell
lines associated with the listed primary cells. A comple-
mentary phase could be the application of this methodology
to animal models in those situations in which it could be
required. This project will be an integral part of the new
Human Diabetes Proteome Project (HDPP) initiative to gener-
ate systems-level knowledge into diabetes-associated cellular
changes.
5.8.  Mitochondria  and  beta-cell  function
Insulin resistance alone does not result in T2DM because
hypersecretion of insulin from beta-cells is able to maintain
normal glucose homeostasis. However, subsequent decline
of insulin secretion will lead to impaired glucose homeosta-
sis and the development of the disease. Islets from diabetic
human donors secrete much less insulin in response to glu-
cose even when correcting for total insulin content [31]. These
results suggest beta-cell dysfunction as an early event during
diabetes progression prior to beta-cell loss.
The beta-cell acts as a fuel sensor. The uptake and
metabolism of nutrients in beta-cells is linked to the formation
of downstream signals stimulating insulin secretion. This pro-
cess is known as metabolism-secretion coupling and is tightly
linked to mitochondrial function [32]. Mitochondria are not
only the site where nutrients are oxidized but the organelle
also exports metabolites that are activators of insulin gran-
ule exocytosis. This is best studied for the ATP/ADP ratio,
which increases as a result of mitochondrial activation. This
rise induces the closure of the KATP channel, depolarization
of the plasma membrane resulting in calcium inﬂux, which
stimulates insulin granule exocytosis.
Consistent with the central importance of mitochondria,
inhibition of respiration blocks insulin secretion. Further-
more,  mitochondrial dysfunction has been observed in islets
from individuals with T2DM. Both insulin secretion and the
ATP/ADP response to glucose were strongly impaired in islets
from donors with T2DM [33]. These ﬁndings were supported by
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ramatic morphological abnormalities of mitochondrial ultra-
tructure in these islets.
We will study the molecular mechanism leading to mito-
hondrial abnormalities during T2DM disease progression.
hese studies will be initiated with mitochondria from INS-
E beta cells following nutrient oversupply. The changes in
he mitochondrial proteome observed in this model sys-
em can then be tested in a more  focused manner studying
itochondria of rodent or human islets. This analysis will be
omplemented by functional studies of beta-cell mitochon-
ria at the single cell level, which are designed to elucidate
he mechanisms leading to beta-cell dysfunction during T2DM
rogression.
.9.  Cardiovascular  diseases:  focus  on  antiplatelet
herapy
latelets play a key role in the pathogenesis and the ischemic
omplications of atherosclerosis, a major macro-vascular
omplication of diabetes [34]. Although antiplatelet drugs
sually belong to the ﬁrst line treatment in cardiovascular
atients, its efﬁcacy in preventing recurrence of ischemic
vents in those patients with diabetes is controversial. Aspirin
s the most prescribed antiplatelet drug for the long term
revention of ischemic events [35]. Through acetylation of
yclooxygenase 1 (COX-1), aspirin abolishes platelet-derived
hromboxane (Tx) A2 production and impairs platelet acti-
ation. However, despite appropriate antiplatelet therapy,
ascular events recur in a signiﬁcant proportion of patients,
aising the possibility of biological “aspirin resistance” being
mplicated in these treatment failures [36]. Indeed, variability
f the biological effect of aspirin has been described. The abil-
ty of platelets to generate TxA2 is best reﬂected by serum
xB2, a stable spontaneous breakdown product of TxA2. A
rospective study on 700 consecutive aspirin-treated patients
resenting for diagnostic cardiac catheterization showed that
igh TxB2 levels (present in 8% of the population) were inde-
endently associated with cardiovascular ischemic events
uring a 2-year follow-up (HR 2.4, 95% CI 1.1–5.5) [37]. Deter-
inants of the variability of aspirin response are not well
nderstood but diabetes and platelet turnover are consis-
ently associated with increased residual platelet reactivity
n these patients [38–40]. This ﬁnding is consistent with the
ower, if any, cardiovascular protective effect of aspirin in
iabetic patients [41]. The effect of both aspirin and gluco-
oxicity relies on protein derivatization. The discovery of the
dentity and function of the glycated blood proteins gener-
ted by chronic hyperglycemia and the impact of glycation
n the acetylation potency of aspirin would thus be of a
onsiderable help to further understand some of the underly-
ng mechanisms implicated in protein dysfunction associated
o glucotoxicity as well as the impaired protective effect
f aspirin in diabetic patients. We  will thus investigate the
mpact of chronic hyperglycemia on the blood glycated pro-
eome (plasma, red blood cells, white blood cells and platelets)
rom type 2 diabetic patients compared to age and sex-
atched non-diabetic controls. We will also evaluate the
rotein acetylation proﬁle after in vitro and in vivo treatment
ith aspirin in those diabetic patients and controls. These
xperiments will help us to delineate the impact of protein i c s 1 ( 2 0 1 3 ) 3–11 9
glycation on the acetylation potency of aspirin as well as
the putative prevention of aspirin in inhibiting protein gly-
cation.
5.10.  Bioinformatics  and  network  based  biology
This bioinformatics and network-biology (systems biology)
will be supported through several layers of essential infor-
mation, data and knowledge. Protein information required for
analysis of datasets will be obtained from UniProtKB/Swiss-
Prot, that contains high quality, manually curated functional
data on all proteins of interest to the HDPP consortium. This
data is complemented by additional information available in
neXtProt, a human-speciﬁc knowledge resource that provides
data provided by third party databases in addition to those
available in UniProtKB/Swiss-Prot, including HPA [18] and Bgee
[42], of high relevance to HUPO and HDPP. The bioinformat-
ics group of HDPP will speciﬁcally support HDPP by including
datasets provided by HUPO-projects and initiatives, includ-
ing the data from the HDPP itself. In order to maximize the
access to experimental datasets, the ProteomeXchange mech-
anism will be used as main channel for high quality datasets
maintenance.
6.  Collaborative  vision  and  integration  into
the  B/D-HPP  program
Disease initiatives are translational in nature and only a
worldwide international constellation of expertise can deliver
the breadth and depth of translational knowledge, such as tar-
geted by the HPP. The project will be multidisciplinary and
executed based on a solid collaboration between universities,
hospitals, institutes, large-scale enterprises, and – potentially
– SMEs. The challenging objectives deﬁned in the present dia-
betes application are not achievable by any one partner in
isolation because of the complementary expertise only being
accessible through the present consortium. All partners are
experts in their respectively assigned work packages. The
integration into the overarching HPP initiative will favor col-
laborations and exchange of information across all C-HPP
and B/D-HPP initiatives. Results obtained by the consortium
will be disseminated through ProteomeXchange and PRIDE
into Human Proteome/Diabetes repositories. They will further
be published in peer-reviewed journals and at international
conferences and workshops. The results will be used in educa-
tional activities such as student courses, as well as M.Sc. and
Ph.D. projects. An (External) Scientiﬁc Advisory Board (SAB)
will be formed, which will include key players in the ﬁeld of
diabetes and network biology as well as members of other HPP
initiatives.
7.  Concluding  remarks
The HDPP initiative has been started to combine and lever-
age a high level of uniquely complementary expertise in the
ﬁeld of diabetes and its associated complications. HDPP will
execute several omics-rooted projects with systems biology
character. The project was ofﬁcially launched at the 11th HUPO
meeting in Boston, USA. At the next (12th) HUPO meeting in
 t e o 
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Yokohama, Japan, HDPP will present ﬁrst results related to the
early deliverables and milestones.
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